{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T07:33:55Z","timestamp":1768203235070,"version":"3.49.0"},"reference-count":27,"publisher":"American Psychological Association (APA)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Experimental and Clinical Psychopharmacology"],"DOI":"10.1037\/1064-1297.10.3.268","type":"journal-article","created":{"date-parts":[[2005,10,7]],"date-time":"2005-10-07T19:32:30Z","timestamp":1128713550000},"page":"268-275","source":"Crossref","is-referenced-by-count":23,"title":["Multimodal evaluation of risperidone for destructive behavior: Functional analysis, direct observations, rating scales, and psychiatric impressions."],"prefix":"10.1037","volume":"10","author":[{"given":"Maria G.","family":"Valdovinos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deborah A.","family":"Napolitano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer R.","family":"Zarcone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica A.","family":"Hellings","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dean C.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen R.","family":"Schroeder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"15","published-online":{"date-parts":[[2002]]},"reference":[{"key":"r1_10.1037\/1064-1297.10.3.268","doi-asserted-by":"crossref","unstructured":"Aman. Drugs in mental retardation: Treatment or tragedy? 10 215 1985","DOI":"10.3109\/13668258508998641"},{"key":"r2_10.1037\/1064-1297.10.3.268","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3109\/10401239309148981","article-title":"Efficacy of psychotropic drugs for reducing self-injurious behavior in the developmental disabilities.","volume":"5","author":"Aman","year":"1993","journal-title":"Annals of Clinical Psychiatry","ISSN":"https:\/\/id.crossref.org\/issn\/1040-1237","issn-type":"print"},{"key":"r3_10.1037\/1064-1297.10.3.268","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1098-2779(1999)5:4<253::AID-MRDD2>3.0.CO;2-R"},{"key":"r4_10.1037\/1064-1297.10.3.268","first-page":"283","article-title":"The Aberrant Behavior Checklist--Community: Factor validity and effect of subject variables for adults in group homes.","volume":"100","author":"Aman","year":"1995","journal-title":"American Journal of Mental Deficiency","ISSN":"https:\/\/id.crossref.org\/issn\/0002-9351","issn-type":"print"},{"key":"r5_10.1037\/1064-1297.10.3.268","first-page":"492","article-title":"Psychometric characteristics of the Aberrant Behavior Checklist.","volume":"89","author":"Aman","year":"1985","journal-title":"American Journal of Mental Deficiency","ISSN":"https:\/\/id.crossref.org\/issn\/0002-9351","issn-type":"print"},{"key":"r6_10.1037\/1064-1297.10.3.268","first-page":"133","article-title":"Neuroleptics.","volume-title":"Psychotropic medications and developmental disabilities: The international consensus handbook","author":"Baumeister","year":"1998"},{"key":"r7_10.1037\/1064-1297.10.3.268","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/BF02684957","article-title":"Prevalence and patterns of psychotropic medication use by adults with mental retardation living in community settings.","volume":"7","author":"Bisconer","year":"1996","journal-title":"Journal of Developmental and Physical Disabilities","ISSN":"https:\/\/id.crossref.org\/issn\/1056-263X","issn-type":"print"},{"key":"r8_10.1037\/1064-1297.10.3.268","doi-asserted-by":"publisher","DOI":"10.1023\/A:1025926817928"},{"key":"r9_10.1037\/1064-1297.10.3.268","first-page":"305","article-title":"Risperidone in young children with pervasive developmental disorders and other developmental disabilities.","volume":"5","author":"Demb","year":"1996","journal-title":"Journal of Child and Adolescent Psychopharmacology","ISSN":"https:\/\/id.crossref.org\/issn\/1044-5463","issn-type":"print"},{"key":"r10_10.1037\/1064-1297.10.3.268","first-page":"364","article-title":"Pharmocotherapy for self-injurious behavior: Preliminary tests of the D1 hypothesis.","volume":"25","author":"Gualtieri","year":"1989","journal-title":"Psychopharmacology Bulletin","ISSN":"https:\/\/id.crossref.org\/issn\/0048-5764","issn-type":"print"},{"key":"r11_10.1037\/1064-1297.10.3.268","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1176\/ajp.141.1.20","article-title":"Tardive dyskinesia and other clinical consequences of neuroleptic treatment in children and adolescents.","volume":"141","author":"Gualtieri","year":"1984","journal-title":"The American Journal of Psychiatry","ISSN":"https:\/\/id.crossref.org\/issn\/0002-953X","issn-type":"print"},{"key":"r12_10.1037\/1064-1297.10.3.268","unstructured":"Gunter. 1993"},{"key":"r13_10.1037\/1064-1297.10.3.268","unstructured":"Guy. 1976"},{"key":"r14_10.1037\/1064-1297.10.3.268","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-199611000-00025"},{"key":"r15_10.1037\/1064-1297.10.3.268","doi-asserted-by":"publisher","DOI":"10.1023\/A:1025854532079"},{"key":"r16_10.1037\/1064-1297.10.3.268","first-page":"85","article-title":"Instruments for assessing effects of psychotropic medication.","volume-title":"Psychotropic medication and developmental disabilities: The international consensus handbook","author":"Hurley","year":"1998"},{"key":"r17_10.1037\/1064-1297.10.3.268","doi-asserted-by":"crossref","unstructured":"Iwata. 1994","DOI":"10.5982\/jgarden.1994.18"},{"key":"r18_10.1037\/1064-1297.10.3.268","doi-asserted-by":"publisher","DOI":"10.1023\/A:1025813607005"},{"key":"r19_10.1037\/1064-1297.10.3.268","first-page":"721","article-title":"Clinical and economic aspects of risperidone treatment in adults with mental retardation and behavioral disturbance.","volume":"32","author":"Lott","year":"1996","journal-title":"Psychopharmacology Bulletin","ISSN":"https:\/\/id.crossref.org\/issn\/0048-5764","issn-type":"print"},{"key":"r20_10.1037\/1064-1297.10.3.268","volume-title":"Self-injurious behavior: Analysis, assessment, and treatment.","author":"Luiselli","year":"1991"},{"key":"r21_10.1037\/1064-1297.10.3.268","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1089\/cap.1995.5.273","article-title":"Risperidone in adults with autism or pervasive developmental disorder.","volume":"5","author":"McDougle","year":"1995","journal-title":"Journal of Child and Adolescent Psychopharmacology","ISSN":"https:\/\/id.crossref.org\/issn\/1044-5463","issn-type":"print"},{"key":"r22_10.1037\/1064-1297.10.3.268","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-199705000-00020"},{"key":"r23_10.1037\/1064-1297.10.3.268","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.55.7.633"},{"key":"r24_10.1037\/1064-1297.10.3.268","doi-asserted-by":"crossref","unstructured":"Shores. Classroom interactions of children with behavior disorders. 1 27 1993","DOI":"10.1177\/106342669300100106"},{"key":"r25_10.1037\/1064-1297.10.3.268","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3758\/BF03203616","article-title":"A multiple option observation system for experimental studies: MOOSES.","volume":"27","author":"Tapp","year":"1995","journal-title":"Behavior Research Methods, Instruments, & Computers","ISSN":"https:\/\/id.crossref.org\/issn\/0743-3808","issn-type":"print"},{"key":"r26_10.1037\/1064-1297.10.3.268","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/j.1600-0447.1993.tb03350.x","article-title":"Risperidone as add-on therapy in behavioral disturbances in mental retardation: A double-blind, placebo-controlled cross-over study.","volume":"87","author":"Van den Borre","year":"1993","journal-title":"Acta Psychiatrica Scandinavica","ISSN":"https:\/\/id.crossref.org\/issn\/0001-690X","issn-type":"print"},{"key":"r27_10.1037\/1064-1297.10.3.268","doi-asserted-by":"publisher","DOI":"10.1352\/0895-8017(2001)106<0525:EOROAB>2.0.CO;2"}],"container-title":["Experimental and Clinical Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/psycnet.apa.org\/journals\/pha\/10\/3\/268.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,6]],"date-time":"2024-02-06T20:18:29Z","timestamp":1707250709000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.apa.org\/doi\/10.1037\/1064-1297.10.3.268"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002]]},"references-count":27,"aliases":["10.1037\/\/1064-1297.10.3.268"],"journal-issue":{"issue":"3","published-online":{"date-parts":[[2002]]}},"alternative-id":["2002-15488-011","12233987"],"URL":"https:\/\/doi.org\/10.1037\/1064-1297.10.3.268","relation":{},"ISSN":["1936-2293","1064-1297"],"issn-type":[{"value":"1936-2293","type":"electronic"},{"value":"1064-1297","type":"print"}],"subject":[],"published":{"date-parts":[[2002]]}}}